Utilizing Nanoparticles to Overcome Anti-PD-1/PD-L1 Immunotherapy Resistance in Non-Small Cell Lung cancer: A Potential Strategy

Utilizing Nanoparticles to Overcome Anti-PD-1/PD-L1 Immunotherapy Resistance in Non-Small Cell Lung cancer: A Potential Strategy

Yuli Ge,1 Qiong Zhou,2 Fan Pan,2 Rui Wang1 1Department of Medical Oncology, Jinling Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, People’s Republic of China; 2Department of Medical Oncology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ge Y, Zhou Q, Pan F, Wang R
Format:	Article
Language:	English
Published:	Dove Medical Press 2025-02-01
Series:	International Journal of Nanomedicine
Subjects:	pd-1/pd-l1 immunotherapy resistance mechanisms immunosuppression tme nanoparticles pro-inflammatory tme
Online Access:	https://www.dovepress.com/utilizing-nanoparticles-to-overcome-anti-pd-1pd-l1-immunotherapy-resis-peer-reviewed-fulltext-article-IJN
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

TAMs and PD-1 networking in esophageal cancer: literature review
by: M. Yerolatsite, et al.
Published: (2025-03-01)

Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends
by: Talaiti Tuergan, et al.
Published: (2025-12-01)

Characterization and functional evaluation of JS207, a novel bispecific antibody against human PD-1 and VEGFA
by: Shihua Lin, et al.
Published: (2025-06-01)

Spatial transcriptomics reveals tumor microenvironment heterogeneity in EBV positive diffuse large B cell lymphoma
by: Mei-yao He, et al.
Published: (2025-05-01)

Molecular subtyping dictates therapeutic response to anti-PD-L1 immunotherapy in ES-SCLC
by: Qianqian Zhang, et al.
Published: (2025-05-01)

An updated review of immunotherapy in esophageal cancer: PD-L1 footprint
by: Juan Yao, et al.
Published: (2024-05-01)

Enhancing CAR-T Efficacy: The Role of Anti PD-1/PD-L1 Checkpoint Inhibitors in Modern Cancer Treatment
by: Rishi Kant, et al.
Published: (2025-06-01)

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
by: Yizhou Zhang, et al.
Published: (2024-12-01)

Comparison of treatment outcome between first‐line combination immunotherapy (anti‐PD‐L1 or anti‐PD1) with or without chemotherapy and chemotherapy alone in advanced non‐small cell lung cancer patients in tertiary care hospital
by: Danainut Naratornsirakul, et al.
Published: (2024-07-01)

Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free survival and PD-L1 status
by: David Dora, et al.
Published: (2023-12-01)

Metabolism of tryptophan in non-small lung cancer patients with different effect of PD-1 / PD-L1 inhibitors immunotherapy
by: E. Yu. Zlatnik, et al.
Published: (2022-06-01)

The potential role of HPV oncoproteins in the PD-L1/PD-1 pathway in cervical cancer: new perspectives on cervical cancer immunotherapy
by: Jin Li, et al.
Published: (2024-12-01)

Current perspectives on tertiary lymphoid structures and PD-1/PD-L1 signaling pathway in the immunotherapy of hepatocellular carcinoma
by: Hao-Dong QIAO, et al.
Published: (2023-10-01)

Theoretical investigation on PD-L1-In-1 for cancer immunotherapy via density functional theory
by: Bijay Sijapati Magar, et al.
Published: (2025-08-01)

Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1
by: Suli Wang, et al.
Published: (2024-11-01)

Dissecting the link between PD-1/PD-L1-based immunotherapy and cancer pain: mechanisms, research implications, and artificial intelligence perspectives
by: Marco Cascella, et al.
Published: (2024-12-01)

Serum soluble PD‐1 plays a role in predicting infection complications in patients with acute pancreatitis
by: Xingxing Yu, et al.
Published: (2021-03-01)

Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies
by: Annapaola Montagner, et al.
Published: (2024-12-01)

Relative expression orderings based prediction of treatment response to Anti-PD-1 immunotherapy in advanced melanoma
by: Yaru Gao, et al.
Published: (2025-03-01)

N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1
by: Bar Kaufman, et al.
Published: (2025-05-01)

Perspectives of Targeting Autophagy as an Adjuvant to Anti-PD-1/PD-L1 Therapy for Colorectal Cancer Treatment
by: Nasrah ALKhemeiri, et al.
Published: (2025-05-01)

The Potential of PD-1 and PD-L1 as Prognostic and Predictive Biomarkers in Colorectal Adenocarcinoma Based on TILs Grading
by: Nur Rahmah Rasyid, et al.
Published: (2024-11-01)

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
by: Miren Zuazo, et al.
Published: (2019-06-01)

Cryoablation synergizes with anti-PD-1 immunotherapy induces an effective abscopal effect in murine model of cervical cancer
by: Xiaoming Yang, et al.
Published: (2025-01-01)

Advances in PD-1/PD-L1 pathway inhibitors in the treatment of thyroid cancer: mechanisms and clinical therapeutic perspectives
by: Xizi Li, et al.
Published: (2025-08-01)

PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution
by: Ryohei Kondo, et al.
Published: (2025-05-01)

Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer
by: Hongshu Li, et al.
Published: (2025-04-01)

The current status and prospects of gut microbiota combined with PD-1/PD-L1 inhibitors in the treatment of colorectal cancer: a review
by: Min Deng, et al.
Published: (2025-05-01)

Efficacy and safety of PD-1 and PD-L1 inhibitors in advanced colorectal cancer: a meta-analysis of randomized controlled trials
by: Zhenzi Wang, et al.
Published: (2024-12-01)

TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives
by: Zhuohong Yan, et al.
Published: (2025-05-01)

Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Inﬂuenza A (H1N1)
by: A. V. Malyarchikov, et al.
Published: (2021-08-01)

Targeting PD-1 post-translational modifications for improving cancer immunotherapy
by: Jie Shi, et al.
Published: (2025-06-01)

Engineered PD-L1 co-expression in PD-1 knockout and MAGE-C2-targeting TCR-T cells augments the cytotoxic efficacy toward target cancer cells
by: Fangxin Zhao, et al.
Published: (2025-04-01)

Anti-PD-1 antibody enhances homeostatic proliferation–induced antitumor immunity during lymphopenia recovery
by: Zike Yang, et al.
Published: (2025-05-01)

NIR-II photo-accelerated polymer nanoparticles boost tumor immunotherapy via PD-L1 silencing and immunogenic cell death
by: Tian Zhang, et al.
Published: (2025-04-01)

Role of PD-1/PD-L1 signaling axis in oncogenesis and its targeting by bioactive natural compounds for cancer immunotherapy
by: Yogesh Godiyal, et al.
Published: (2024-12-01)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
by: Miao Wang, et al.
Published: (2021-12-01)

Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy
by: Shuyan He, et al.
Published: (2025-01-01)

The association of PD-L1 expression status and the PD-1/PD-L1 inhibitor-related toxicity profile in non-small cell lung cancer
by: Qian Zhu, et al.
Published: (2025-04-01)

Co‐Expression of MHC‐II and ANXA1: Mediators of PD‐1/PD‐L1 Therapy Resistance in Breast Cancer
by: Hao Wang, et al.
Published: (2025-08-01)